Fayad, Z. A. | bioRxiv Science

bioRxiv2026

Frequency Shift Imaging Using an Adiabatic SLR Self-Refocused Pulse for Positive-Contrast SPION Imaging at 7T

Abstract: Purpose: Superparamagnetic iron oxide nanoparticles (SPION) are widely used as MRI contrast agents for cell tracking and molecular imaging. However, their detection using conventional T2/T2* weighted and susceptibility-weighted MRI relies on negative contrast (signal voids), which lacks specificity because similar hypointense signals can arise from other sources of magnetic susceptibility. This study introduces Frequency Shift Imaging (FSI), a positive-contrast technique based on an adiabatic Shinnar-Le Roux (SLR) self-refocused pulse that addresses the limited specificity of conventional SPION imaging. Methods: An adiabatic self-refocused RF pulse was designed using the SLR algorithm for frequency-selective positive-contrast imaging. The optimized pulse had a spectral bandwidth of 370 Hz, a peak RF amplitude of 14 T, and a duration of 15 ms. FSI data were acquired on a 7T MRI scanner. Phantom experiments used agarose-embedded 30 nm cell-labeled SPION at 0%, 25%, 75%, and 100% concentrations (pure). In vivo validation was performed following intramuscular SPION injection into the hind limb of a mouse. FSI images were compared with conventional acquisitions. Results: Quantitative phantom analysis showed normalized FSI signal intensities of 25.02% and 75.16% for samples containing 25% and 75% labeled cells, respectively, demonstrating an approximately proportional relationship between FSI signal and labeled-cell concentration. In vivo, FSI generated localized hyperintense positive contrast at the SPIO injection site, providing improved conspicuity and localization compared with the corresponding negative-contrast signal void. Discussion and Conclusion: FSI enables robust, B1-insensitive, positive-contrast SPION imaging at 7T with reduced echo time and SAR compared to paired adiabatic approaches, supporting its potential for quantitative cell tracking and molecular imaging applications.

bioengineering↗

bioRxiv2022

A Single Multipurpose FSH-Blocking Therapeutic for Osteoporosis and Obesity

Pharmacological and genetic studies over the past decade have established FSH as an actionable target for diseases affecting millions, notably osteoporosis, obesity and Alzheimers disease (AD). Blocking FSH action prevents bone loss, fat gain and AD-like features in mice. We recently developed a first-in-class, humanized, epitope-specific FSH blocking antibody, MS-Hu6, with a KD of 7.52 nM. Using a GLP-compliant platform, we now report the efficacy of MS-Hu6 in preventing obesity and osteoporosis in mice, and parameters of acute safety in monkeys. Biodistribution studies using 89Zr-labelled, biotinylated or unconjugated MS-Hu6 in mice and monkeys showed localization to bone, bone marrow and fat depots. MS-Hu6 displayed a {beta} phase t[1/2] of 13 days (316 hours) in humanized Tg32 mice, and bound endogenous FSH. We tested 215 variations of excipients using the protein thermal shift assay to generate a final formulation that rendered MS-Hu6 stable in solution upon freeze-thaw and at different temperatures, with minimal aggregation, and without self-, cross-, or hydrophobic interactions or appreciable binding to relevant human antigens. MS-Hu6 showed the same level of "humanness" as human IgG1 in silico, and was non-immunogenic in ELISPOT assays for IL-2 and IFN{gamma} in human peripheral blood mononuclear cell cultures. We conclude that MS-Hu6 is efficacious, durable and manufacturable, and is therefore poised for future human testing as a multipurpose therapeutic.

pharmacology and toxicology↗